Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-21841220
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-21841220
Ann Rheum Dis 2020; DOI: 10.1136/annrheumdis-2020-218992
Annals of the Rheumatic Diseases 2020;79:760-770
Annals of the Rheumatic Diseases 2020;79:778-786
Arthritis Res Ther 2020;22:142
RMD Open 2020;6:e001174 doi:10.1136/rmdopen-2020-001174
Arthritis Rheumatol. 2020 Sep; 72(9): 1435–1446.
Intern Med. 2020;59(6):817-821
Ann Rheum Dis. 2020 Jan 22. pii: annrheumdis-2019-216655.
Rheumatology (Oxford) 2019;58(10):1755–66